Cellectis said it is quitting its CAR-T business and pivoting to “in vivo” gene editing. The French biotech cited a shifting therapeutic landscape and offloaded its lead programs as part of the change, marking a significant retrenchment for a company previously associated with donor-derived cell therapy ambitions. The pivot matters for developers watching platform risk—especially in cell therapy, where manufacturing complexity, payer access, and competitive differentiation can quickly force strategy changes. It also redirects capital and talent toward gene editing efforts intended to avoid ex vivo cell production. For investors and partnership counterparties, the decision signals a narrowing of near-term cell therapy deliverables and an emphasis on in vivo editing timelines.